Jazz Pharmaceuticals

Jazz Pharmaceuticals's $3.2M in disclosed federal lobbying puts it in the mid-tier of registered filers. Spending in the seven-figure range is common for established trade groups, mid-size corporations, and advocacy organizations that maintain a steady but not aggressive presence on Capitol Hill.

Across the 5-year window from 2020 to 2024, Jazz Pharmaceuticals's annual disclosed lobbying spend has climbed meaningfully — from $525K in 2020 to $765K in 2024, a change of +46%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.

Jazz Pharmaceuticals's disclosed lobbying focuses on a narrow 3-issue footprint. A focused issue list usually means the organization concentrates its federal engagement on a small set of bills or rulemakings directly relevant to its core business.

1 of 2 lobbyists reported by Jazz Pharmaceuticals (50%) disclose prior federal government service — a high revolving-door share. The LDA cover sheet flags any "covered position" the lobbyist held in the executive branch, Congress, or a senior staff role within the past two years.

Among the named bench, lobbyists with disclosed prior federal service include Christopher J. White (Former Deputy Chief of Staff, U.S. House of Representatives). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Jazz Pharmaceuticals ranks #34 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Jazz Pharmaceuticals's $3.2M sits 81% below the sector average.

Jazz Pharmaceuticals's LobbySpend Influence Score of 56/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.

Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.